Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Survival in Patients with Plasma Cell Myeloma
Leuk Lymphoma; ePub 2017 Jul 21; Santiago, et al
Certain patients with plasma cell myeloma are prone to worse overall survival, according to a retrospective study involving 130 individuals. Investigators quantified the hematogone population by flow cytometric immunophenotyping in post-transplant bone marrow biopsy specimens from adult patients who received autologous stem cell transplant for either plasma cell myeloma (n=57) or diffuse large B-cell lymphoma (n=73). Among the results:
- 8 in every 10 patients had <5% marrow hematogones post-transplant.
- Hematogone percentages >10% were seen in only 4 patients, and were not linked with disease progression.
- There was a positive link between the post-transplant day and hematogone percentage within the first year after transplant, and a negative link thereafter.
- Patients with ≥5% hematogones in any post-transplant flow cytometry study, or with increased hematogones 100 days post-transplant had worse overall survival.
Santiago V, Lazaryan A, McClune B, McKenna R, Courville E. Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome. [Published online ahead of print July 21, 2017]. Leuk Lymphoma. doi:10.1080/10428194.2017.1352094.